Treatment of acute hepatitis C with interferon alfa-2b.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  New England Journal of Medicine

• Publication date

  2001-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMOA011232PMID 11794193
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study

  2001cited by this paper
• Acute hepatitis C

  2001cited by this paper
• Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

  2000cited by this paper
• Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus

  2000cited by this paper
• High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for acute hepatitis C

  2000cited by this paper
• Immune control of HIV-1 after early treatment of acute infection

  2000cited by this paper
• Interaction between the Hepatitis C Virus and the Immune System

  2000cited by this paper
• Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.

  2000cited by this paper
• Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome

  2000cited by this paper
• Low frequency of cirrhosis in a hepatitis C (genotype 1b) single‐source outbreak in germany: A 20‐year multicenter study

  2000cited by this paper
• Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C.

  2000cited by this paper
• CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained

  2000cited by this paper
• Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.

  1999cited by this paper
• Treatment of acute hepatitis C with interferon alpha 2b prevents chronicity.

  1999cited by this paper
• Liver transplantation for chronic viral hepatitis.

  1999cited by this paper
• Acute sporadic non‐A, non‐B hepatitis in Northeastern Brazil: Etiology and natural history

  1999cited by this paper
• Infection with an unenveloped DNA virus (TTV) in patients with acute or chronic liver disease of unknown etiology and in those positive for hepatitis C virus RNA.

  1999cited by this paper
• Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C.

  1999cited by this paper
• Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.

  1999cited by this paper
• Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin.

  1999cited by this paper
• EASL International Consensus Conference on Hepatitis C

  1999cited by this paper
• The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

  1999cited by this paper
• Role of the specific T‐cell response for clearance and control of hepatitis C virus

  1999cited by this paper
• EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement.

  1999cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Natural beta interferon in acute type-C hepatitis patients: a randomized controlled trial.

  1998cited by this paper
• [The prevalence of hepatitis C virus infection].

  1998cited by this paper
• Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

  1998cited by this paper
• Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection.

  1998cited by this paper
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

  1998cited by this paper
• Recurrence of hepatitis C virus after loss of virus specific CD4+ T cell response in acute hepatitis C

  1998cited by this paper
• Gastric adenocarcinoma and kidney transplantation

  1998cited by this paper
• Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

  1997cited by this paper
• Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

  1997cited by this paper
• Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia.

  1997cited by this paper
• Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

  1997cited by this paper
• Natural history of hepatitis C

  1997cited by this paper
• National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C

  1997cited by this paper
• Prolonged treatment (one year) of histologically advanced chronic hepatitis C with recombinant interferon alpha

  1996cited by this paper
• Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.

  1996cited by this paper
• Immunology Taught by Viruses

  1996cited by this paper
• High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study.

  1996cited by this paper
• A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C.

  1994cited by this paper
• Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group.

  1994cited by this paper
• A multicenter randomized controlled trial of recombinant interferon‐α2b in patients with acute transfusion‐associated hepatitis C

  1994cited by this paper
• A randomized controlled trial of recombinant interferon α-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C

  1994cited by this paper
• The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha

  1994cited by this paper
• Outcome of Acute Hepatitis C and Role of Alpha Interferon Therapy

  1994cited by this paper
• Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis.

  1993cited by this paper
• Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells

  1993cited by this paper
• Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells

  1993cited by this paper
• Interferon‐α in acute posttransfusion hepatitis C:. A randomized, controlled trial

  1992cited by this paper
• Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial.

  1992influential reference
• Resolution of acute hepatitis C after therapy with natural beta interferon.

  1991cited by this paper
• Interferon therapy for acute posttransfusion non-A, non-B hepatitis: response with respect to anti-hepatitis C virus antibody status.

  1991cited by this paper
• Liver transplantation for chronic viral hepatitis.

  1991cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Advancing Viral Defense: Unravelling the Potential of Host-Directed Antivirals Against SARS-CoV-2

  2025cites this paper
• Interferons Inhibit Ebola Virus Infection of Human Keratinocytes

  2025cites this paper
• What goes up must come down: dynamics of type 1 interferon signaling across the lifespan

  2025cites this paper
• Akute Virushepatitis

  2024cites this paper
• Acute Hepatitis C: Current Status and Future Perspectives

  2024cites this paper
• Therapeutic Effectiveness of Interferon-α2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience

  2023cites this paper
• Active-targeting long-acting protein-glycopolymer conjugates for selective cancer therapy.

  2023cites this paper
• A Synopsis of Hepatitis C Virus Treatments and Future Perspectives

  2023cites this paper
• Breakthroughs in hepatitis C research: from discovery to cure

  2022cites this paper
• Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study

  2022cites this paper
• Total Joint Arthroplasty Should Not Be Delayed in Hepatitis C Patients After Successful Treatment Achieving a Sustained Viral Load

  2022cites this paper
• Hepatitis C Virus prediction based on machine learning framework: a real-world case study in Egypt

  2022cites this paper
• Distinct effects of treatment with two different interferon-alpha subtypes on HIV-1-associated T-cell activation and dysfunction in humanized mice

  2021cites this paper
• Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C

  2021cites this paper
• Cytokine Therapy

  2021cites this paper
• Prevalence of Needle Stick Injury among Surgeons

  2021cites this paper
• Management of Patients with Acute Hepatitis C

  2021cites this paper
• Acute and Chronic Hepatitis

  2021cites this paper
• Acute Hepatitis: Treat Immediately or Give a Chance to Spontaneously Clear?

  2020cites this paper
• Human Acute and Chronic Viruses: Host-Pathogen Interactions and Therapeutics

  2020cites this paper
• Prevalence of Hepatitis C Virus Infection in the Veteran Population Undergoing Total Joint Arthroplasty: An Update.

  2020cites this paper
• The pros and cons of interferons for oncolytic virotherapy.

  2020cites this paper
• Viral Hepatitis: Acute Hepatitis

  2019cites this paper
• Bypassing the bottleneck: intentional hepatitis C transmission with organ transplant.

  2019cites this paper
• Acute Hepatitis C

  2019cites this paper
• Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.

  2019cites this paper
• Role of Interferon (IFN)&agr; in “Cocktails” for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions

  2019cites this paper
• Needle stick injury reporting among surgeons in tertiary hospitals of Lahore

  2019cites this paper
• Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage

  2019cites this paper
• Computational approaches for improving treatment and prevention of viral infections

  2019cites this paper
• [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection].

  2018cites this paper
• Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan

  2018cites this paper
• Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate

  2018cites this paper
• Aktuelle Arzneimitteltherapie der Hepatitis C

  2018cites this paper
• Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City

  2018cites this paper
• The MEK1/2-ERK Pathway Inhibits Type I IFN Production in Plasmacytoid Dendritic Cells

  2018cites this paper
• S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“

  2018cites this paper
• Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men

  2018cites this paper
• Collagen Hydrogel Functionalized with Collagen-Targeting IFNA2b Shows Apoptotic Activity in Nude Mice with Xenografted Tumors.

  2018cites this paper
• Assessment of adherence behaviors for the self-reporting of occupational exposure to blood and body fluids among registered nurses: A cross-sectional study

  2018cites this paper
• [Current drug treatment of hepatitis C : Useful therapy algorithms taking into consideration economical aspects].

  2018cites this paper
• Management of acute HCV infection in the era of direct-acting antiviral therapy

  2018cites this paper
• Direct-acting antiviral treatment of acute hepatitis C virus infections

  2018cites this paper
• Therapeutic spectrum of interferon‐β in ischemic stroke

  2018cites this paper
• Current Treatment Approach in Acute Hepatitis C Infection

  2017cites this paper
• HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs

  2017influential citation
• Elevated Liver Enzymes: Emergency Department-Focused Management.

  2017cites this paper
• Hepatitis C Virus NS5A Targets Nucleosome Assembly Protein NAP1L1 To Control the Innate Cellular Response

  2017cites this paper
• Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.

  2017cites this paper
• Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1–Infected Individuals: SWIFT-C

  2017cites this paper
• Sofosbuvir in the treatment of early HCV infection in HIV-infected men

  2017cites this paper
• A case of dual oral therapy for elderly patients with acute hepatitis C

  2017cites this paper
• Study of the Humoral Immune Response towards HCV Genotype 4 Using a Bead-Based Multiplex Serological Assay

  2017cites this paper
• Treatment optimization for HIV/HCV co-infected patients

  2017cites this paper
• Viral and host factors associated with outcomes of hepatitis C virus infection (Review).

  2017cites this paper
• Diagnosis, Management And Prevention Of Hepatitis C In Pakistan 2017.

  2017cites this paper
• Guideline for Management of Hepatitis C Infection

  2017cites this paper
• New Onset of Multi-Drug Hypersensitivity Reaction after Successful Treatment of Hepatitis C with Ledipasvir-Sofosbuvir in CKD: A Case Report.

  2017cites this paper
• Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.

  2017cites this paper
• Hepatitis C virus infection

  2017cites this paper
• Investigation of the hepatitis C virus RNA polymerase NS5B in solution by nuclear magnetic resonance and its interaction with intrinsically disordered domain 2 of the NS5A protein

  2017cites this paper
• Cutting out the roots of acute hepatitis C.

  2017cites this paper
• Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence

  2017cites this paper
• Global dynamics of a viral infection model with full logistic terms and antivirus treatments

  2017cites this paper
• Impact of nanomedicine on hepatic cytochrome P450 3A4 activity: things to consider during pre-clinical and clinical studies

  2017cites this paper
• Correlates of Long-term Immune Protection in Hepatitis C Virus (HCV) Exposed Non-reinfected Individuals

  2017cites this paper
• Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.

  2017cites this paper
• Hepatic Failure

  2016cites this paper
• Hepatitis B and C in Children

  2016cites this paper
• Treatment of hepatitis C in injecting drug users in the Perth metropolitan area

  2016cites this paper
• Treatment of Early Hepatitis C Infection in HIV-Infected Men—When to Treat, Whom, and with What?

  2016cites this paper
• Hepatitis B and Hepatitis C viral infection: A Review

  2016cites this paper
• Treatment of Acute Hepatitis C

  2016cites this paper
• Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients.

  2016cites this paper
• Dissolving microneedle-based intradermal delivery of interferon-α-2b

  2016cites this paper
• ICBS and ECBS Chemical Biology Meeting 2015 - Let Them Come to Berlin!

  2016cites this paper
• Vom Kompetenznetz Hepatitis (HepNet) zur Deutschen Leberstiftung

  2016cites this paper
• [From the national competence network for viral hepatitis (HepNet) emerged the German Liver Foundation (Deutsche Leberstiftung)].

  2016cites this paper
• Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations

  2016cites this paper
• Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort

  2016cites this paper
• KASL clinical practice guidelines: management of hepatitis C

  2016cites this paper
• Interferon lambda polymorphisms: validation and characterisation

  2016cites this paper
• Conditions for eradicating hepatitis C in people who inject drugs: A fibrosis aware model of hepatitis C virus transmission.

  2016cites this paper
• Target Population : patients with acute hepatitis C virus infection Setting :

  2015cites this paper
• An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17.

  2015cites this paper
• Trust Guideline for the Management of Incidents which have the potential to transmit Blood Borne Viruses A clinical guideline recommended for use

  2015cites this paper
• Hepatitis C Infection , Genotypes and Frequency of Interleukin-28 B Polymorphisms

  2015cites this paper
• Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity

  2015cites this paper
• Distinct Features in Natural History and Outcomes of Acute Hepatitis C

  2015cites this paper
• Viral hepatitis and HIV co-infection in the UK Collaborative HIV cohort (UK CHIC) study

  2015influential citation
• Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections

  2015cites this paper
• Occupational Exposures: Epidemiology and Protocols

  2015cites this paper
• Acute HCV Infection: Diagnosis, Epidemiology and Current Treatment Options

  2015cites this paper
• Leber – Gallenwege – Pankreas

  2015cites this paper
• Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis

  2015cites this paper
• Knowledge of occupational safety by hospital cleaners and hospital managers towards HIV and other blood borne pathogens transmission in Abakaliki region in Eastern Nigeria

  2015cites this paper
• Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013

  2015cites this paper
• CD3(+)CD56(+) Natural Killer-Like T Cells Display Anti-HCV Activity but Are Functionally Impaired in HIV(+) Patients With Acute Hepatitis C

  2015cites this paper
• 156 – Hepatitis C

  2015cites this paper
• [Management of hepatitis B virus and hepatitis C virus infection in chronic kidney failure].

  2015cites this paper